TABLE 3.
Logistic regression analysis based on clinical characteristics
| Clinical characteristics | MR4.5 by 42 weeks | Backward selection (p < 0.15) | ||
|---|---|---|---|---|
| OR (95% CI) | p‐value | OR (95% CI) | p‐value | |
| Age, years | 1.076 (0.980–1.181) | 0.1241 | 1.051 (0.983–1.124) | 0.1476 |
| Sex (female/male) | 0.950 (0.094–9.597) | 0.9656 | ||
| TKI, 2G‐TKI/IM | 25.769 (0.398–999.999) | 0.1267 | ||
| Time since diagnosis, 36 months~<60 months/others | 0.241 (0.009–6.579) | 0.3993 | ||
| BCR‐ABL IS baseline, MR4 (<0.01)/MMR (≥0.01) | 195.5 (2.979–999.999) | 0.0135 | 55.969 (3.808–822.639) | 0.0033 |
| TM5614 dose, 150/180 mg/day | 0.269 (0.018–4.124) | 0.3456 | ||
Abbreviations: 2G, second‐generation; CI, confidence interval; IM, imatinib; OR, odds ratio; TKI, tyrosine kinase inhibitor.